Press release                                 

                                     Bioventix plc                                 

                            ("Bioventix" or the "Company")                         

     Pre Diagnostics and Bioventix enter collaboration on blood-based beta amyloid 
                              Alzheimer's diagnostic test                          

    Oslo, 31 May 2016, Norwegian Alzheimer's diagnostics company Pre Diagnostics AS
    today announced a collaboration with leading UK antibody specialist Bioventix
    plc (BVXP).  Under the terms of the agreement Bioventix will develop and
    provide antibodies for Pre Diagnostics new patient-friendly IVD test for
    dementia based on mid domain beta amyloid detection.

    The inventor of Pre Diagnostics' approach, Professor Tormod Fladby of Akershus
    University Hospital and the University of Oslo commented on the clinical need:
    "Alzheimer's disease develops over many years and the brain adapts to the
    disease.  It can take 10-20 years before dementia onset.  By then is it too
    late to reverse the disease symptoms and brain degeneration.  Early detection
    of disease activity is likely to allow more effective treatment early in the
    disease course, and may improve quality of life and delay disease progression
    for patients with Alzheimer's disease.  Our research, on which the new test is
    based, shows that Alzheimer's disease is accompanied by systemic responses in
    certain white blood cells (macrophages) unique to the disease which can be
    accurately measured in the blood samples of patients."

    Pre Diagnostics CEO Håkon Sæterøy commented.  "By working with Bioventix,
    utilising their in-depth antibody and ELISA expertise, we aim to further
    optimise our current prototype blood-based Alzheimer's test which has already
    shown promise in preliminary testing". 

    According to Sæterøy, the company is now on track for launching a research only
    test in 2017:  "It is now widely accepted that a new blood-based test with high
    accuracy in the early disease stages is essential to accelerate effective drug
    development and intervention within the Alzheimer's space.  We aim to develop
    such tests that effectively demonstrate any intervention effect on the key
    disease mechanisms."

    Peter Harrison, CEO of Bioventix plc said: "We are delighted to be involved
    with Pre Diagnostics and their beta amyloid project.  We are very impressed by
    the Oslo-based group and their research partners, their thorough approach to
    basic science and their ability to apply this to clinical research.  We believe
    that our antibody and assay capabilities can be applied to beta amyloid, thus
    facilitating an improved Alzheimer test for the Oslo group.  It will be
    exciting to work with them towards further clinical testing and
    commercialisation".  

    For further information, please contact:

    Pre Diagnostics AS                                                            
    Håkon Sæterøy              Chief Executive Officer   Tel: +47 956 95 175      
                                                                                  
    Bioventix plc                                                                 
    Peter Harrison             Chief Executive Officer   Tel: 01252 728 001       
                                                                                  
    finnCap Ltd                                                                   
    Geoff Nash/Simon Hicks     Corporate Finance         Tel: 020 7220 0500       
    Steve Norcross             Corporate Broking                                  

    About Pre Diagnostics AS

    Pre Diagnostics (www.pre-diagnostics.com) is an innovative Norwegian diagnostic
    company that seeks to create value for patients, partners, and investors by
    developing pioneering and patient-friendly, in-vitro diagnostic (IVD) products
    for early detection of diseases. The company's proprietary concept is built
    upon the scientific premise that a disease evokes systemic responses in
    macrophages unique to that disease which can be accurately measured in the
    blood samples of patients. Pre Diagnostics aims to be a leader in the diagnosis
    of early Alzheimer's disease and is thus focused on the development of IVD
    biomarker products that use well-established technologies and procedures. The
    company protects its technology with an evolving patent portfolio            

    About Bioventix plc:

    Bioventix (www.bioventix.com) specialises in the development and commercial
    supply of high-affinity monoclonal antibodies with a primary focus on their
    application in clinical diagnostics, such as in automated immunoassays used in
    blood testing.  The antibodies created at Bioventix are generated in sheep and
    are of particular benefit where the target is present at low concentration and
    where conventional monoclonal or polyclonal antibodies have failed to produce a
    suitable reagent.  Bioventix currently offers a portfolio of antibodies to
    customers for both commercial use and R&D purposes, for the diagnosis or
    monitoring of a broad range of conditions, including heart disease, cancer,
    fertility, thyroid function and drug abuse.  Bioventix currently supplies
    antibody products and services to the majority of multinational clinical
    diagnostics companies.  Bioventix is based in Farnham, UK and its shares are
    traded on AIM under the symbol BVXP.

    About Alzheimer's disease:

    Alzheimer disease is the leading cause of dementia among older people. An
    estimated 10 percent of Americans over the age of 65 and half of those over age
    85 have Alzheimer's. More than five million Americans currently suffer from the
    disease, and the number is projected to balloon to 10-15 million over the next
    several decades. Alzheimer's is now the third most expensive disease to treat
    in the U.S., costing society close to $100 billion annually.

    Alzheimer's is a progressive, incurable disease. The earliest damage occurs in
    the entorhinal cortex, hippocampus and basal forebrain, which are small,
    specialized structures in the brain that play a critical role in memory. The
    disease is characterized by amyloid plaques (deposits in the brain of a sticky
    protein called amyloid beta peptide) and neurofibrillary tangles (abnormally
    twisted forms of the protein tau, in the long branches of neurons). The cause
    remains a mystery.